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Abstract
Objective
To evaluate the psychometric properties of the HIV Disability Questionnaire (HDQ) among
people living with HIV (PLHIV) in London, United Kingdom (UK).
Methods
This is a cross-sectional measurement study. We recruited and administered the self-
reported HDQ, seven criterion measures, and a demographic questionnaire with adults liv-
ing with HIV accessing HIV care. We determined median and interquartile ranges (IQR) for
disability presence, severity and episodic scores (range 0–100). We calculated Cronbach’s
alpha (α) Kuder-Richardson-20 (KR-20) statistics for disability and episodic scores respec-
tively (internal consistency reliability), smallest detectable change (SDC) for each HDQ
severity item and domain (precision), and tested 36 a priori hypotheses assessing correla-
tions between HDQ and criterion scores (construct validity).
Results
Of N = 243 participants, all were male, median age 40 years, 94% currently taking antiretro-
viral therapy, and 22% living with�2 concurrent health conditions. Median HDQ domain
scores ranged from 0 (IQR: 0,7) (difficulties with day-to-day activities domain) to 27 (IQR:
14, 41) (uncertainty domain). Cronbach’s alpha for the HDQ severity scale ranged from 0.85
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(95% Confidence Interval (CI): 0.80–0.90) in the cognitive domain to 0.93 (95%CI: 0.91–
0.94) in the mental-emotional domain. The KR-20 statistic for the HDQ episodic scale ran-
ged from 0.74 (95%CI: 0.66–0.83) in the cognitive domain to 0.91 (95%CI: 0.89–0.94) in the
uncertainty domain. SDC ranged from 7.3–15.0 points on the HDQ severity scale for difficul-
ties with day-to-day activities and cognitive symptoms domains, respectively. The majority
of the construct validity hypotheses (n = 30/36, 83%) were confirmed.
Conclusions
The HDQ possesses internal consistency reliability and construct validity with varied preci-
sion when administered to males living with HIV in London, UK. Clinicians and researchers
may use the HDQ to measure the nature and extent of disability experienced by PLHIV in
the UK, and to inform HIV service provision to address the health-related challenges among
PLHIV.
Background
For the 36.9 million people living with HIV (PLHIV) globally [1], effective treatment offers
normal life expectancy [2]. Consequently, PLHIV surviving past 50 years of age are increasing
at exponential and unprecedented rates [3]. In 2017, more than a third (39%) of PLHIV receiv-
ing HIV care in the UK were aged 50 years or older [4]. Moreover by 2028 it is estimated over
half of people in UK HIV care will be aged�50 years [5] with repeated patterns forecast in
Europe and North America [6]. As people live longer with chronic HIV infection, they are sus-
ceptible to health conditions arising from the underlying infection, potential side effects of
treatments, and ageing [7], resulting in increasingly more prevalent multi-morbidity [8]. Com-
mon conditions include bone and joint disorders [9,10], mental health conditions [11], cardio-
vascular disease [12–14], cancer [15,16], and neurocognitive decline [17,18]. The presence of
these conditions can create physical, mental, cognitive and social health-related challenges that
are conceptualised as disability [19].
Disability is multi-dimensional [20] and episodic in nature [19]. The Episodic Disability
Framework in HIV defines disability as: physical, cognitive, mental and emotional symptoms
and impairments, difficulties carrying out day-to-day activities, challenges to social inclusion,
and uncertainty or worrying about the future [19]. These can fluctuate on a daily basis and
over the life course. Furthermore, these dimensions of disability can be exacerbated or allevi-
ated by extrinsic contextual factors (e.g. social support and stigma) and intrinsic contextual
factors (e.g. living strategies and personal attributes) [21].
As people live longer, disability assessment and treatment will be a critical component to
HIV care. Measuring disability in the context of HIV is important for determining the preva-
lence and impact of disability, identifying interventions that may reduce disability, and to
inform disability-inclusive programming [22]. A valid and reliable patient-reported outcome
measure (PROM) for PLHIV that can be used by PLHIV, community-based service organisa-
tions, and health providers, is critical to identify the nature and extent of disability experienced
by PLHIV, assess the burden of disability living with HIV, and determine the effect of medical
and rehabilitation interventions in mitigating disability. This knowledge could be used by cli-
nicians, social service providers, health service commissioners, and policy makers, to help
guide policy and program development and inform the allocation of health care resources to
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improve care, treatment and support, designed to reflect the long-term nature of HIV care
[23].
Existing HIV-specific health status instruments tend to focus on impairments and do not
fully capture the breadth of disability, specifically lacking items related to social inclusion and
uncertainty [21]. Impairment data alone is not an adequate proxy for disability, as people with
the same impairment can experience different types and degrees of limitations, depending on
personal and environmental factors [24]. The majority of studies assessing disability among
PLHIV focused on measurements of single impairments [25], providing a relatively narrow
understanding of disability [26] that is insufficient in capturing the multi-dimensional nature
of HIV [19,25]. To our knowledge, there is no known self-reported data on disability, beyond
impairments alone, experienced by PLHIV in the UK.
The HIV Disability Questionnaire (HDQ) is a new self-administered HIV-specific PROM
developed to measure the presence, severity and episodic nature of disability among PLHIV
[27]. The HDQ is comprised of six dimensions of disability that were derived from the Episodic
Disability Framework, a conceptual framework developed from the perspective of PLHIV to
characterise the health-related challenges living with HIV [28]. The HDQ is novel in that it is
the sole HIV-specific PROM of disability [29]. However, disability may vary depending on the
context and region of the world in which PLHIV live [30]. Therefore, it is critical to assess psy-
chometric properties with a population and setting that is representative of the context in
which questionnaires will be used [31]. The HDQ possessed sensibility (including face and
content validity) with a sample of adults living with HIV in Canada [32]. The HDQ demon-
strated construct validity and test-retest reliability when used with PLHIV in Canada [33], and
construct validity and internal consistency reliability when used with PLWH in Ireland [34]
and the United States [35]. Compared to these contexts, the UK has a different healthcare sys-
tem [36] with more PLHIV accessing antiretroviral therapy and achieving viral suppression
[4,37], rendering the relevance and applicability of the HDQ to PLHIV in other developed
countries, such as the UK unknown.
Our aim was to assess the measurement properties, specifically internal consistency reliabil-
ity, precision of measurement, and construct validity, of the HDQ for its ability to measure dis-
ability experienced by adults living with HIV in London, UK.
Methods
We conducted a cross-sectional measurement study, to assess construct validity and reliability
of the HDQ. We used quality criteria for assessing measurement properties of health status
questionnaires to guide our methodological approach [31]. We recruited adults, 18 years of
age or older, living with HIV who attended an outpatient HIV clinic in central London, UK
between March 2016 and May 2017. Potential participants were approached during regular
clinic visits for their participation in the study. All participants provided written informed con-
sent. Ethical approval was obtained from the London Dulwich Research Ethics Committee
and Health Research Authority (IRAS 165402) and the HIV/AIDS Research Ethics Board at
the University of Toronto, Canada (Protocol #34126). A data sharing agreement was approved
between St Stephen’s Clinical Research, Cicely Saunders Institute King’s College London, and
the University of Toronto.
We administered the HDQ, a demographic questionnaire, and seven health status criterion
measures (Patient Health Questionnaire (PHQ-9) [38], General Anxiety Disorder (GAD)
Questionnaire [39], Fatigue Severity Scale [40], Wellness Thermometer [41], Epworth Sleepi-
ness Scale (ESS) [42], Everyday Memory Questionnaire (EMQ) [43], and International HIV
Dementia Scale (IHDS) [44]. Participants had the option to either complete the questionnaires
Validity, reliability and precision of the HIV Disability Questionnaire
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at their clinic visit, or take them home and return later via the post. Clinical characteristics
were obtained from participants’ electronic medical records including number of years since
HIV diagnosis, antiretroviral therapy use, most recent CD4 count (cells/mm3), viral load
(cells/ml), and diagnosed concurrent health conditions.
HIV disability questionnaire (HDQ)
The HDQ, English Version 10.5, 2017, is a 69 item self-administered questionnaire developed
from the Episodic Disability Framework, through a community-academic partnership, to
describe the presence, severity and episodic nature of disability experienced by PLHIV [19,27].
The HDQ includes six disability domains: i) physical, ii) cognitive and, iii) mental and emo-
tional health symptoms and impairments, iv) uncertainty, v) difficulty with day-to-day activi-
ties, and vi) challenges to social inclusion, and one ‘good day/bad day’ health classification
item. Participants are asked to rate the level of presence and severity of each health challenge
on a given day ranging from 0 (not at all) to 4 (extreme). HDQ scores range from 0 to 100 with
higher scores indicating a greater presence, severity and episodic nature of disability. The
HDQ has demonstrated sensibility, validity, internal consistency reliability and test-retest reli-
ability in samples of adults living with HIV in Canada, Ireland and the United States [33–35].
Median administration time is 8–15 minutes.
We calculated disability presence, severity and episodic scores on the HDQ [45]. Disability
presence scores were calculated by summing the number of health challenges experienced for
each domain and total HDQ and transforming them to a score out of 100. Disability severity
scores were calculated by summing individual item scores from each domain and then linearly
transforming them into domain disability severity scores out of 100. Episodic disability scores
were calculated by summing the number of challenges identified as episodic in each domain
and then transforming to a score out of 100. We summed the number of participants and
proportion who completed the HDQ on a ‘good day’ or ‘bad day’ living with HIV (health
classification). We computed missing response rates for the disability, episodic, and health
classification sections of the HDQ accordingly. To maximise HDQ data, we performed mean
(severity) or median (episodic) imputation on items with less than�10% missing responses.
List wise deletion was performed for criterion measures with missing responses. We examined
the distribution of HDQ item scores for a floor effect (defined as>15% of responses at the bot-
tom (0) of the HDQ scale) and ceiling effect (defined as>15% of responses at the high end (4)
of the HDQ scale).
Demographic questionnaire
Participants completed a self-reported questionnaire to capture demographic characteristics
including; age (years), gender, ethnicity, nationality, sexuality, smoking status, household
description, employment status, educational attainment, and whether registered with GP
physician.
Reliability—internal consistency
We calculated the Cronbach’s alpha (α) (severity scales) and Kuder-Richardson-20 statistics
(episodic scales) for the HDQ domain scores to assess internal consistency reliability (degree
to which the items within the instrument are correlated with each other) [α and KR-20>0.8
defined as acceptable for individual patients] [46].
Validity, reliability and precision of the HIV Disability Questionnaire
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Precision of measurement
Standardised Error of Measurement (SEM) is a measure of precision of an instruments ability
to estimate the true state of a concept. We used Wyrich criteria [47] to calculate the SEM for
each item and domain score to determine the precision of measurement, meaning how accu-
rate the observed HDQ score is with the participants’ true HDQ scores. [SEM = standard
deviation�sqrt (1-Cronbach alpha)]. We then calculated the smallest detectable change (SDC)
to determine the range in which we can be 95% confident that the true HDQ is within this
range. [Observed score +/- 1.96�SEM].
Construct validity
Measuring disability poses several challenges, with a wide range of disability definitions, and
varying approaches to disability measurement [24,48]. In the absence of a ‘gold standard’
approach to measuring disability [49], we assessed the accuracy of the HDQ by testing a priori
hypotheses about predicted relationships between scores of measures that relate to disability
[38–44] with scores of the HDQ.
We determined the extent to which the HDQ relates or does not relate to the seven criterion
measures [38–44]. The appropriate subscale scores of the HDQ were compared to criterion
measures using correlation analysis. We tested 8 primary and 29 exploratory hypotheses theo-
rising relationships between data collected in the HDQ and criterion measures using correla-
tion coefficients (Pearson if scores normally distributed, Spearman if not normally
distributed). Hypotheses included convergent and divergent construct validity testing based
on previous construct validity assessment of the HDQ [33–35], and aimed to maximise data
related to dimensions of the HDQ and subscale scores data collected from criterion measures.
Correlation coefficients of |�0.30|, |�0.50| and |�0.70|, were defined as ‘weak’, ‘moderate,’
and ‘strong,’ respectively [31]. We considered the HDQ to possess construct validity if results
confirm at least 75% of the predetermined hypotheses [31]. All data analyses were performed
using SAS software version 9.4 [50].
Sample size
Our required sample size was estimated based on our construct validity analysis. To detect a
weak correlation from our construct validity hypothesis, r = 0.30, with a power of 0.80, and
alpha of 0.05, we required a sample of n = 85, inflated to at least 102 for an estimated 20% miss-
ing response rate at item level.
Results
Participant characteristics
Of the 244 participants recruited, all but one identified as male (Table 1). We excluded the one
participant who identified as female resulting in a total of 243 participants in this study. The
median age of participants was 40 years (20% were�50 years), with a median year of diagnosis
of 2012 (96% diagnosed 1996 or after). The majority were employed (87%), 94% were currently
taking antiretroviral therapy, and 82% had an undetectable viral load (Table 1). Fifty-four per-
cent (54%) of participants were living with a concurrent health condition in addition to HIV,
and 22% reported living with at least two or more concurrent health conditions. The most
common concurrent health condition was mental health (e.g. anxiety, depression, personality
disorder, or schizophrenia).
Validity, reliability and precision of the HIV Disability Questionnaire
PLOS ONE | https://doi.org/10.1371/journal.pone.0213222 July 10, 2019 5 / 17
Table 1. Characteristics of participants in analysis (n = 243).
Age (n = 240)
Median Age (years) (IQR) (Range) 40 years (33, 48)
(Range: 22–67)
Number of participants (%)�50 years 48 (20.0%)
Gender (n = 243) Number (%)
Male 243 (100.0%)
Ethnicity (n = 241)
White 213 (88.4%)
Black Caribbean or Black African 6 (2.5%)
Indian, Pakistani or Chinese 5 (2.1%)
Other 17 (7.1%)
Nationality (n = 243)
United Kingdom of Great Britain and Northern Ireland 143 (58.8%)
European Union (e.g. France, Italy, Ireland, Spain, Poland, Greece, Portugal, Germany) 75 (30.9%)
United States, North America 8 (3.3%)
South America 4 (1.6%)
Asia-Pacific Region 8 (3.3%)
Other (Middle East, or Africa) 5 (2.1%)
Sexuality (n = 243)
Homosexual 234 (96.3%)
Heterosexual, bisexual, unknown 9 (3.7%)
Smoking Status (n = 237)
Current Smoker 58 (24.5%)
Participants’ household description: I am living. . .. (n = 238)
Alone 83 (34.9%)
With a spouse or partner 81 (34.0%)
With a flatmate/friend 65 (27.3%)
Other (e.g. living with a child <18 years, living in an institutionalised residence or care home) 9 (3.8%)
Employment status (n = 242)
Employed: regular, occasional/part-time employment, self-employed, freelance 210 (86.8%)
Not employed: Benefits (including Disability Living Allowance and Employment Support
Allowance)
12 (5.0%)
Not Employed: Income from savings, investments or pension 15 (6.2%)
Support from spouse, parents, children, relatives, or friends 5 (2.1%)
Highest level of education completed (n = 243)
University 177 (72.8%)
College/vocational training 48 (19.8%)
Secondary 18 (7.4%)
Year of HIV diagnosis (n = 241)
Median Year of HIV Diagnosis (IQR)(Range) 2012 (2007, 2014)
(Range: 1983–
2016)
Diagnosed in 1996 or after 231(95.9%)
Taking antiretroviral therapy (n = 242)
Yes 228 (94.2%)
CD4 Count (cells/mm3) (n = 239)
Median (IQR) (Range) Median: 676 (508,
875)
Range: 190–7545
Viral Load (n = 236)
(Continued)
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Data completeness
The median number of missing responses for HDQ items was 7 (2.9%) for the presence and
severity scale and 13 (5.3%) for the episodic scale. Proportion of missingness was <3% for the
severity scale and<10% for the episodic scale. Rates for missing responses for each item were
higher on the episodic scale, with 11.7% (n = 109/929) of missing episodic scale responses also
missing severity scale responses. However 77.7% (n = 637/820) of missing episodic scale
responses were present in conjunction with a severity scale score of zero, which might be
attributed to some participants skipping this item if they did not feel as if they had that specific
health challenge. There were 10 missing responses (4.1%) for the ‘good day / bad day’ item on
the HDQ.
HDQ scores
HDQ item scores were not normally distributed. A floor effect was evident in all 69 HDQ
items (100%) with >20% of the sample responding 0 (no challenge), and 52 of the items
(75.4%) had a floor effect >40%. Floor effect was most prominent in the physical (95%), cogni-
tive (100%), and day-to-day activities (100%) domains. A ceiling effect was not present in any
of the HDQ items.
Highest disability presence score was in the uncertainty domain, followed by domains men-
tal-emotional health symptoms, challenges to social inclusion, physical symptoms, and cogni-
tive symptoms. Highest disability severity score also was in the uncertainty domain, followed
by challenges to social inclusion, mental-emotional symptoms, physical symptoms, and cogni-
tive symptoms. Physical symptoms had the highest episodic score (Table 2). The number of
participants who identified as completing the HDQ on a ‘good day’ living with HIV was 193
(79%).
Criterion measures
Similar to the HDQ, criterion measure summary scores were skewed to the healthier range of
the scales (Shapiro Wilk Test for all criterion items and summary scores p<0.0001; data not
shown). Median PHQ-9 scores were 4 out of possible range 0–27 (IQR: 2, 8) indicating ‘mini-
mal’ depression severity. Median GAD scores were 10 out of possible range 0–21 (IQR: 8, 14)
indicating low to moderate anxiety. Median scores of the international HIV dementia scale
Table 1. (Continued)
Undetectable (<40 cells/ml) 193 (81.8%)
Registered with General Physician (GP) (n = 243)
Yes 214 (88.1%)
Concurrent Health Conditions� (n = 241)
Diagnosed with other medical condition 130 (53.9%)
Living with�2 concurrent health conditions 52 (21.6%)
Diagnosed with concurrent mental health condition (eg: anxiety, depression, personality
disorder or schizophrenia)
20 (8.3%)
Diagnosed with concurrent malignancy, opportunistic infection, or immune reconstitution
inflammatory syndrome
18 (7.5%)
Diagnosed with concurrent hypertension 18 (7.5%)
IQR: Interquartile Range
�as determined from the electronic health record.
https://doi.org/10.1371/journal.pone.0213222.t001
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was 12 out of possible range 0–12 (IQR: 7,12), and 8 out of possible range 0–52 (IQR: 4, 15) on
the EMQ, indicating high cognitive health. Median scores on the Wellness Thermometer was
7 out of possible range 0–10 (IQR: 5, 8) indicating participants reported to tend to feel well.
Median scores of the Fatigue Scale were 29 out of possible range 9–63 (IQR: 21, 38) indicating
participants may be approaching fatigue. Median scores on the ESS was 6 out of possible range
0–64 (IQR: 3, 9) indicating no evidence of abnormal daytime sleepiness in this sample.
Reliability—Internal consistency
HDQ severity scores. All individual items correlated with the HDQ Total Severity Score
>0.2 except for Item #8 –‘I have trouble swallowing food’ (r = 0.14; p = 0.03), and Item #15 –‘I
am unintentionally losing weight’ (r = 0.19; p = 0.03), and each item correlated with its corre-
sponding domain score >0.20.
HDQ episodic scores. All individual items correlated with the HDQ Total Episodic Score
>0.20 except for Item #8 (r = 0.11; p = 0.08) and Item #15 (r = 0.15; p = 0.02), and each item
correlated with its corresponding domain score >0.20.
Cronbach’s alpha for the entire HDQ was 0.96 (95% Confidence Interval (CI): 0.96–0.97)
and ranged from 0.85 (95%CI: 0.80–0.90) in the cognitive domain to 0.93 (95% CI: 0.91–0.94)
in the mental-emotional domain. The KR-20 statistic for the entire episodic scale of the HDQ
was 0.95 (95% CI: 0.94–0.96) and ranged from 0.74 (95% CI: 0.66–0.83) in the cognitive
domain to 0.91 (95% CI: 0.89–0.94) in the uncertainty domain (Table 3).
Precision of measurement
The standardised error of measurement (SEM) for HDQ items ranged from 0.05 (Item #8 –I
have trouble swallowing food) to 0.28 (Item #64 –I find it hard to talk to others about my ill-
ness). Level of precision for the HDQ domain scores ranged from most precise in the
Table 2. HDQ Summary scores for participants in the UK sample (n = 243).
HDQ Subscale (# items) HDQ Presence
(Median, IQR)
(Range)
HDQ Severity Score
(Median, IQR)
(Range)
HDQ Episodic Presence Score (Median; IQR)
(Range)�
Physical symptoms and Impairments (20 items) 25 (15, 45)
Range: 0–90
9 (4, 18)
Range: 0–58
5 (0, 20)
Range 0–80
Cognitive symptoms and impairments
(3 items)
33 (0, 67)
Range: 0–100
8 (0,25)
Range: 0–100
0 (0, 0)
Range: 0–100
Mental-emotional health symptoms and impairments (11
items)
54 (27, 82)
Range: 0–100
18 (7, 34)
Range: 0–89
0 (0, 27)
Range: 0–100
Uncertainty
(14 items)
64 (43, 86)
Range: 0–100
27 (14, 41)
Range: 0–98
0 (0,7)
Range: 0–86
Difficulties with Day-to-Day Activities
(9 items)
0 (0,22)
Range: 0–100
0 (0, 7)
Range: 0–61
0 (0,0)
Range: 0–89
Challenges to Social Inclusion (12 items) 33 (17, 58)
Range: 0–100
12 (4, 27)
Range: 0–81
0 (0,0)
Range: 0–83
Total HDQ Score 38 (22, 57)
Range: 0–93
14 (8, 23)
Range: 0–70
2 (0, 16)
Range: 0–81
Higher scores indicate greater presence, severity and episodic nature of disability.
Bold indicates the highest score across all domains
�For the episodic scores, due to the higher rate of missingness we conducted a post hoc comparison and found no difference in episodic scores post median imputation.
https://doi.org/10.1371/journal.pone.0213222.t002
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difficulties with day-to-day activities domain (SEM: 3.71; SDC: 7.29) to the least precise in the
cognitive symptoms domain (SEM: 7.68; SDC: 15.05) (Table 4).
Construct validity
Of the 36 construct validity hypotheses (8 primary, 28 exploratory), seven (88%) primary, 23
(28%) exploratory, and 30 (83%) of the total hypotheses were confirmed (Table 5).
Discussion
The HDQ demonstrated internal consistency reliability and construct validity among a com-
munity dwelling sample of males living with HIV in an urban UK setting. Internal consistency
reliability was achieved with Cronbach’s alpha and KR-20 statistics (scores >0.8) for all
domain and total scores for episodic and severity scores, except for the cognitive domain for
the episodic scale. This suggests that collectively items in the HDQ are homogenous within the
six HDQ domains to collectively measure the broader construct of disability at one time point
[34]. Precision of measurement varied with subscales scores demonstrating highest levels of
precision in the difficulties with day-to-day activities domain (SDC: 7.68), to lowest levels of
precision in the cognitive symptoms domain (SDC: 15.05), suggesting among PLHIV, the
Table 3. Internal consistency reliability for HDQ items (n = 243).
HDQ Items HDQ Severity Scale HDQ Episodic Scale
Cronbach’s Alpha (Raw
values)
95% confidence
interval
Kuder-Richardson Statistic (Raw
values)
95% confidence
interval
HDQ Items (all) 0.96 0.96, 0.97 0.95 0.94, 0.96
Physical Symptoms and Impairments 0.87 0.85, 0.90 0.84 0.80, 0.88
Cognitive Symptoms and Impairments 0.85 0.80, 0.90 0.74 0.66, 0.83
Mental and Emotional Health Symptoms and
Impairments
0.93 0.91, 0.94 0.90 0.87, 0.92
Uncertainty 0.90 0.88, 0.92 0.91 0.89, 0.94
Difficulty with Day-to-Day Activities 0.90 0.86, 0.93 0.82 0.73, 0.91
Challenges to Social Inclusion 0.87 0.84, 0.90 0.84 0.79, 0.89
95% Confidence Interval: asymptotically distribution free (ADF) for non-normal data.
Median imputation of episodic scores; >0.8 defined as acceptable for individual patients
https://doi.org/10.1371/journal.pone.0213222.t003
Table 4. Level of precision of HDQ scores for participants (n = 243).
HDQ Domain Standard
Deviation
Standardised Error of Measurement
(SEM)
Smallest Detectable Change (SDC)
(1.96�SEM)
Physical Symptoms and Impairments 11.02 3.92 7.69
Cognitive Symptoms and Impairments 19.75 7.68 15.05
Mental and Emotional Health Symptoms and
Impairments
21.06 5.64 11.06
Uncertainty 19.39 6.17 12.09
Difficulty with Day-to-Day Activities 11.52 3.71 7.29
Challenges to Social Inclusion 16.48 5.96 11.69
HDQ Total Score 13.45 2.59 5.08
HDQ score range: 0–100
https://doi.org/10.1371/journal.pone.0213222.t004
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Table 5. Construct validity analysis.
Construct Validity Analysis–a priori hypotheses Spearman Correlation Coefficient
(95% Confidence Interval)
Convergent Construct Validity (22 hypotheses) theorizing relationships between data collected in the HIV
Disability Questionnaire (HDQ) and criterion measures
PHQ-9
1) �Scores on PHQ-9 will be strongly correlated (�0.7) with the mental
and emotional symptoms domains of the HDQ.
0.83 (0.63, 0.76)^
2) Scores on PHQ-9 will be moderately correlated (�0.5) with the
uncertainty domain of the HDQ.
0.52 (0.37, 0.57)^
3) Scores on PHQ-9 will be moderately correlated (�0.5) with the
cognitive symptoms and impairments of the HDQ.
0.66 (0.49, 0.66)^
4) Scores on PHQ-9 will be moderately correlated (�0.5) with the
challenges to social inclusion domain of the HDQ.
0.62 (0.45, 0.63)^
General Anxiety Disorder (GAD)– 4 a priori hypotheses
5) �Scores on the General Anxiety Disorder (GAD) questionnaire will be
strongly correlated (�0.7) with the mental and emotional symptom
domains of the HDQ.
0.81 (0.59, 0.73)^
6) Scores on the General Anxiety Disorder (GAD) questionnaire will be
moderately correlated (�0.5) with the uncertainty domain of the HDQ.
0.52 (0.37, 0.57)^
7) Scores on the General Anxiety Disorder (GAD) questionnaire will be
moderately correlated (�0.5) with the cognitive symptoms and
impairments domain of the HDQ.
0.56 (0.41, 0.60)^
8) Scores on the General Anxiety Disorder (GAD) questionnaire will be
moderately correlated (�0.5) with the challenges to social inclusion
domain of the HDQ.
0.61 (0.45, 0.63)^
Fatigue Scale
9) �Scores on the Fatigue Scale will be moderately correlated (�0.5) with
the physical symptoms domain of the HDQ.
0.61 (0.45, 0.63)^
10) Scores on the Fatigue Scale will be moderately correlated (�0.5) with
the difficulties with day-to-day activity domain of the HDQ.
0.57 (0.41, 0.60)^
11) Scores on the Fatigue Scale will be moderately correlated (�0.5) with
the challenges to social inclusion domain of the HDQ.
0.39 (0.26, 0.48)
Wellness Thermometer
12) �Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the HDQ Total Score.
-0.67 (-0.66, -0.50)^
13) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the PHYSICAL domain score on the HDQ.
-0.64 (-0.65, -0.47)^
14) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the COGNITIVE domain score on the HDQ.
-0.41 (-0.49, -0.27)
15) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the MENTAL-EMOTIONAL domain score on the
HDQ.
-0.69 (-0.67, -0.51)^
16) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the UNCERTAINTY domain score on the HDQ.
-0.43 (-0.51, -0.29)
17) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the DIFFICULTIES WITH DAY-TO-DAY
ACTIVITIES domain score on the HDQ.
-0.50 (-0.56, -0.36)^
18) Scores on the Wellness Thermometer will be negatively moderately
correlated (�0.5) with the CHALLENGES TO SOCIAL INCLUSION
domain score on the HDQ.
-0.49 (-0.55, -0.34)
International Dementia Scale
19) �Scores on the International Dementia Scale (Total Score) will be
strongly correlated (�0.7) with the cognitive symptoms domain of the
HDQ.
-0.09 (-0.21, 0.04)
Everyday Memory Questionnaire
(Continued)
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HDQ possesses levels of measurement error and day-to-day variability. Construct validity was
achieved as demonstrated by 88% primary (n = 7/8) and 83% total (n = 30/36) hypothesised
relationships confirmed between the HDQ and criterion measures, which surpassed our 75%
construct validity threshold [31]. Our results build on previous evidence establishing internal
consistency reliability and construct validity of the HDQ in Canada [33], Ireland [34], and the
United States [35], as well as test-retest reliability in Canada [34].
Our study provides the first known assessment of HDQ psychometric properties including
internal consistency reliability, construct validity, and level of precision of HDQ domain scores
in the UK. Internal consistency reliability findings in this UK sample were similar to those
among PLHIV for HDQ severity and episodic scores in Canada (α range: 0.87–0.97; KR-20
Table 5. (Continued)
Construct Validity Analysis–a priori hypotheses Spearman Correlation Coefficient
(95% Confidence Interval)
20) �Scores on the Everyday Memory Questionnaire (EMQ) will be
strongly correlated (�0.7) to the cognitive domain of the HDQ.
0.73 (0.54, 0.67)^
21) Scores on the Everyday Memory Questionnaire will be moderately
correlated (�0.5) with the difficulties with day-to-day activity domain of
the HDQ.
0.54 (0.39, 0.58)^
22) Scores on the Everyday Memory Questionnaire will be moderately
correlated (�0.5) with the challenges to social inclusion domain of the
HDQ.
0.42 (0.29, 0.50)
Divergent Construct Validity (7 hypotheses) theorizing relationships between data collected in the HDQ and
criterion measures
23) ��Scores on the Epworth Sleepiness Scale (ESS) will be weakly
correlated (�0.30) with the HDQ Total Score
0.44 (0.30, 0.51)^
24) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with PHYSICAL domain score on the HDQ.
0.37 (0.23, 0.46)^
25) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with COGNITIVE domain score on the HDQ.
0.40 (0.26, 0.48)^
26) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with MENTAL-EMOTIONAL domain score on the HDQ.
0.34 (0.21, 0.44)^
27) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with UNCERTAINTY domain score on the HDQ.
0.32 (0.18, 0.42)^
28) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with DIFFICULTIES WITH DAY-TO-DAY ACTIVITIES
domain score on the HDQ.
0.43 (0.29, 0.50)^
29) Scores on the Epworth Sleepiness Scale (ESS) will be weakly correlated
(�0.30) with CHALLENGES TO SOCIAL INCLUSION domain score on
the HDQ.
0.37 (0.24, 0.46)^
Known Groups Construct Validity (7 hypotheses) theorizing
relationships between data collected in the HDQ and Self-Perceived State
of Health
�30–36) Participants who completed the HDQ on a ‘good day’ will have
significantly lower scores on all HDQ domain scores and HDQ total
scores; [7 hypotheses]
�HDQ Total was primary hypothesis
All 7 hypotheses confirmed#
(p<0.001)^
Number of HDQ Construct Validity Hypotheses Confirmed
Primary Hypotheses
Exploratory Hypotheses
Total Hypotheses
7/8 (88%)
23/28 (82%)
30/36 (83%)
�Primary hypotheses
Bold^ indicates significance (p<0.001)
#Wilcoxon Test.
https://doi.org/10.1371/journal.pone.0213222.t005
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range: 0.81–0.98) (33), Ireland (α range: 0.84–0.96; KR-20 range: 0.85–0.96) (34), and the
United States (α range: 0.89–0.93; KR-20 range: 0.87–0.96) (35), demonstrating the HDQ is
reliable in measuring disability across high-income settings for PLHIV. Across all settings,
Cronbach’s α or KR-20 were >0.8 for all domains and total scores for both episodic and sever-
ity disability scores, except for the UK cognitive symptoms and impairments domain for the
episodic summary score (KR-20; 0.74). The cognitive domain possesses the fewest number of
items (n = 3), which might account for the lower alpha and KR-20 coefficients in this domain.
Nevertheless, internal consistency reliability coefficients in this study exceeded the Special
Advisory Committee of the Medical Outcomes Trust recommendations, that considers a
Cronbach’s alpha of�0.70 to be acceptable [51].
Precision of the HDQ scores varied across HDQ domains ranging from a SDC of 7.68 (dif-
ficulties with day-to-day activities) to 15.50 (cognitive domain). The smaller the SDC, the
more precise the domain. These values suggest the minimum difference in HDQ domain
scores that would need to occur in order to be confident that an individual had a true change
in disability beyond day-to-day variability or measurement error. Our study is the first to
report on levels of precision of the HDQ. SEM dually reflects precision of an instrument, as
well as the measure’s variation within a patient sample [52]. Nevertheless, results are cross-sec-
tional distribution based scores, and there is no universal consensus on how many SEMs an
individual must change in order for a change in scores to be considered significant, nor clini-
cally important [52]. Future research should assess the interpretability of HDQ scores to deter-
mine the meaning of HDQ scores (cross-sectionally) as well as the minimally clinically
importance difference (MCID) (longitudinally) that represent the important ‘amount’ and
‘importance’ of change in disability over time.
The HDQ possesses construct validity in this UK sample, for its ability to measure disability
as demonstrated by confirmation of total hypothesised relationships between HDQ and crite-
rion measures (83%), which was above our a priori defined threshold of 75% [31]. Construct
validity was similarly demonstrated in Canada (80%) [34] and the United States (87%) [35],
and also was demonstrated in Canada using confirmatory factor analysis [33]. However it is
not possible to compare the UK construct validity results to these previous studies, because the
UK analysis used different criterion measures.
While the HDQ overall demonstrated internal consistency reliability and construct validity
for use among males with HIV in the UK and PLHIV in other high-income countries, reasons
may exist for variations in HDQ scores and properties across different cultural contexts. Diver-
sity in sample populations, recruitment procedures, and mechanisms in which the HDQ and
reference measures were administered, may account for differences in HDQ scores and mea-
surement property coefficients. For instance, UK participants were all male, mostly economi-
cally active and university educated, and living with well controlled HIV, recruited from an
HIV clinic setting, compared with HDQ assessment with PLHIV in Ireland [34]; where fewer
participants were working for pay, and had been living longer with their HIV diagnosis. More-
over participants in Canada [33] were older, living with more comorbidities, and fewer work-
ing for pay, when recruited from community-based organisations. Furthermore, UK
participants completed measurements either during their clinic visit or independently at home
following their routine outpatient HIV care appointments, while Irish participants completed
measures intermittently while seeing various health providers in a busy HIV outpatient setting,
and Canadian participants completed measures consecutively in one single sitting in a quiet
location at an HIV service organisation [34]. This may have introduced inconsistencies in the
way participants responded to items across the questionnaires, creating variations in correla-
tions between measures [34]. Similarly the different criterion measures used in the UK analysis
may have resulted in different estimations of the extent to which we hypothesised items in the
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HDQ would correlate with items included in these criterion measures. Notably, our UK analy-
sis did not include universal measures of disability, therefore to compare to other conditions a
generic disability measurement tool might be recommended (e.g. World Health Organization
Disability Assessment Schedule 2.0) [53]. Hence, measurement properties should be inter-
preted cautiously and specific to the context and sample population.
Our results indicate that the HDQ domain of uncertainty or worrying about the future, was
the most present and severe domain of disability in this UK sample of PLHIV. Uncertainty is a
unique domain of disability within the Episodic Disability Framework [54]. It is also a core dimen-
sion of disability experienced by adults ageing with HIV [55]. Older PLHIV may worry about
HIV specific age-related uncertainties [56] and the trajectory of episodic disability [57]. The role
of uncertainty has also been incorporated into rehabilitation recommendations for adults ageing
with HIV [58], whereby interventions can promote stability, mitigate increasing disability, and
increase time between episodes [57]. Our results indicate that uncertainty can be experienced
across the life-course among a younger sample of PLHIV in the UK, building on existing litera-
ture that uncertainty is the most present and severe domain of disability experienced by PLHIV in
Canada [33], Ireland [34], and the United States [35]. In this UK sample, the most episodic
domain of disability was in the physical domain, which was similarly observed in Ireland [34] and
the United States [35]. This is likely attributed to health challenges in this domain more likely to
fluctuate on a daily basis (e.g. aches and pains, fatigue) opposed to items in the social inclusion
domain (e.g. employment, relationships), which may fluctuate over a longer duration of time. Fur-
ther exploration is warranted into the experiences of uncertainty and episodic health challenges
across the life-course among PLHIV in the UK, and the impact of rehabilitation, such as group-
based interventions [59] to address disability including uncertainty.
Our study has limitations. Firstly participants were all male, mostly aged younger than 50
years, with half the sample living with at least one concurrent health condition, and living in
an urban setting. Therefore this sample is not representative of the UK population of PLHIV,
of which 36% are living in London, 31% are female, with more than one third aged�50 years,
and 73% who are living with at least one concurrent health condition [4,60]. This may demon-
strate recruitment bias, with the sample representing people living ‘well’ with HIV in an urban
setting accessing HIV care. However, the HDQ was developed primarily with men living with
HIV in a large metropolitan city, which may explain the high construct validity in this study,
as this study sample might resemble the sample from which the HDQ was originally derived,
validated, and refined in Ontario, Canada [34]. Nevertheless, evaluation of the psychometric
properties of the HDQ among females living with HIV, and in other low to middle income
contexts is warranted. Secondly, given this study was part of a larger cohort study (IRAS
165402), the criterion measures to assess construct validity were not consistent with previous
HDQ psychometric evaluations [33–35]. Therefore caution should be applied when compar-
ing the validity and reliability of the HDQ. Next, because our goal was to assess the measure-
ment properties of the HDQ in the UK, rather than to measure disability experienced by
PLHIV in the UK, HDQ scores should be interpreted cautiously. Lastly, given the one-time
administration of the HDQ, our analysis was limited to assessing internal consistency reliabil-
ity and construct validity of the HDQ in the UK. Further analysis of the reproducibility,
responsiveness and interpretability of the HDQ among PLHIV in the UK is needed.
Identification of the HDQ as a valid and reliable self-reported disability assessment tool has
important implications for clinical practice, research and policy. Clinicians, HIV community
organisations, and researchers, may use the HDQ to assess disability experienced by PLHIV in
the UK. The aim of the HDQ is to describe the health-challenges experienced among PLHIV,
whether these challenges are related to HIV or other concurrent health conditions [34]. The
HDQ should be administered in combination with other health status instruments that
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capture extrinsic contextual factors (e.g social support, stigma) and intrinsic contextual factors
(e.g. concurrent health conditions) that can influence disability in order to provide a better
understanding of the context in which disability is experienced by PLHIV [27]. To our knowl-
edge, there is no known evidence exploring disability experienced by PLHIV in the UK. Data
on disability experienced by PLHIV, capturing multiple domains of functional limitations, is
therefore required in the UK. Measuring disability can provide information on the nature and
extent of disability, and the health care needs of PLHIV in the UK. This knowledge can help to
inform ways in which HIV services can adopt approaches to better respond to the changing
needs of PLHIV [23], while ensuring function is incorporated into the provision of person-
centered care [61]. Results provide a foundation for future research to utilise the HDQ to
examine the extent and nature of disability among PLHIV in the UK and international cross-
cultural comparisons of disability for PLHIV.
Conclusions
The HDQ possesses internal consistency reliability and construct validity with varied levels of pre-
cision across domain scores, when administered to adults living with HIV in the UK. Results are
specific to a mainly community dwelling sample of males, who are mostly economically active
and university educated, living with well-controlled HIV. Future research should examine HDQ
properties among women living with HIV in the UK, PLHIV in low-to middle income countries,
responsiveness to change, and interpretability of HDQ scores. Future research should consider
cross-cultural, international comparisons of disability, and the ability of the HDQ to detect clini-
cally important changes in disability for examining effectiveness of interventions.
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